State Key Laboratory of Respiratory Disease
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
CO2 Supplement for Treatment of Acute Mountain Sickness
Role: lead
Effect of CPAP on Respiratory Load in COPD
Role: lead
Plasmodium Immunotherapy for Lung Cancer
Role: lead
Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude
Role: lead
Evaluation of Infrared Thermal Imaging in Diagnosis of OSAHS in Children
Role: lead
Acceptable Pressure Range for Continuous Positive Airway Pressure(CPAP) Treatment
Role: lead
Central Sleep Apnea Treated by CO2 Supplied by a Novel Device
Role: lead
Efficacy of Simple Continuous Positive Airway Pressure on Patients With Obstructive Sleep Apnea
Role: lead
Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis
Role: lead
All 9 trials loaded